![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 47, 36605-36611, November 24, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§,
,
,
,
,
, and
From the
Department of Medicine, The Johns Hopkins
School of Medicine, Baltimore, Maryland 21224, the ¶ Schepens Eye
Research Institute and Committee on Immunology and Division of
Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham
and Women's Hospital, Harvard Medical School, Boston, Massachusetts
02114, and the
Molecular Biology Program and Graduate School of
Medical Sciences, Cornell University, Memorial Sloan-Kettering Cancer
Center, New York, New York 10021
Received for publication, August 4, 2000, and in revised form, August 22, 2000
| |
ABSTRACT |
|---|
|
|
|---|
Expression of cytokine genes in T cells is
thought to result from a complex network of antigen- and
mitogen-activated transcriptional regulators. CP2, a factor homologous
to Drosophila Elf-1 and previously found to be a critical
regulator of several viral and cellular genes in response to
developmental signals, is rapidly activated in T helper (Th) cells in
response to mitogenic stimulation. Here we show that overexpression of
CP2 enhances interleukin (IL)-4 promoter-driven chloramphenicol
acetyltransferase expression, while repressing IL-2 promoter activity,
in transiently transfected Jurkat cells. A CP2-protected element,
partially overlapping the nuclear factor of activated T cell-binding P2
sequence, was required for IL-4 promoter activation in
CP2-overexpressing Jurkat cells. This CP2-response element is
the site of a cooperative interaction between CP2 and an inducible
heteromeric co-factor(s). Mutation of conserved nucleotide contacts
within the CP2-response element prevented CP2 binding and significantly
reduced constitutive and induced IL-4 promoter activity. Expression of
a CP2 mutant lacking the Elf-1-homology region of the DNA-binding
domain inhibited IL-4 promoter activity in a dominant negative fashion
in transiently transfected Jurkat cells. Moreover, overexpressed CP2
markedly enhanced, while its dominant negative mutant consistently
suppressed, expression of the endogenous IL-4 gene in the murine Th2
cell line D10. Taken together, these findings point to CP2 as a
critical IL-4 transactivator in Th cells.
Interleukin (IL)1-4 is a
pleiotropic cytokine that modulates the differentiation and the
biologic activities of virtually all cells of hematopoietic origin (1).
IL-4 is typically expressed in (and, at the same time, promotes the
differentiation of) the T helper 2 (Th2) functional subset of
CD4+ T cells, thereby playing a pivotal role in the
regulation of humoral and allergic responses. Conversely, Th1
cell-associated cytokines, such as IL-2 and interferon- It is likely that the commitment toward an IL-4-producing, Th2
phenotype is the outcome of a complex, dynamic interaction of multiple
transcriptional regulators rather than the effect of a single protein.
Irrespective of the cytokine milieu leading to preferential Th1 or Th2
differentiation (2), priming of T cells by antigen or mitogens is a
requirement for IL-4 but not IL-2 production (7). In fact, the IL-4
gene is only transcribed in actively dividing T cells, while IL-2
expression occurs independently of the cell cycle (8). T cell priming
affects the expression and/or activation of a number of factors
presumably involved in the regulation of cytokine genes. For example,
primed T cells express higher levels of NFAT-1 and support greater
NFAT-directed transcription than naive T cells (9). An earlier study
also showed rapid and marked up-regulation of the DNA binding activity of the transcription factor CP2 following mitogenic stimulation of
peripheral blood naive T cells, suggesting the involvement of this
protein in the activation of immediate and/or early genes in these
cells (10).
CP2, also known as leader-binding protein (LBP)-1c (11) or late simian
virus 40 factor (12), is the prototypical member of a novel family of
mammalian proteins sharing a high degree of similarity to Elf-1, a
Drosophila melanogaster tissue-specific factor encoded at
the embryonic lethal locus Grainyhead (11, 13). By
interacting with a hyphenated sequence composed of two directly
repeated 4-base pair (bp) motifs separated by a 6-bp linker
(CNRG-N6-CNR(G/C)) (11, 14), CP2 has been reported to regulate transcription of a number of viral and cellular genes in
response to developmental signals, including those encoding for rat
Cells--
A line of Jurkat T cells, which constitutively
expresses IL-4 and produces IL-2 and interferon- Plasmids--
The IL-4 promoter fragments used in this study
were generated by polymerase chain reaction using human genomic DNA as
a template and cloned into the HindIII and XbaI
sites of a Bluescript vector (Stratagene Cloning Systems, La Jolla,
CA). An XbaI-tailed oligonucleotide, corresponding to bp +36
to +55 of the human IL-4 gene, and one of eight
HindIII-tailed oligonucleotides, corresponding to bp Transfections and Reporter Gene Analysis--
Jurkat cells
(0.5-1 × 106/ml) were transfected with 1 µg of
reporter plasmids and 2 µg of expression plasmids by 48-h culture in
5 ml of complete medium containing 5.2 mg/ml LipofectAMINE (Life
Technologies, Inc.) as described (24). Equal amounts of the
corresponding noncoding vectors were added to control samples to yield
a constant amount (3 µg) of DNA in each transfection. Where
indicated, cells were stimulated 16-18 h before harvest. 40-80 µg
of proteins extracted from each sample were analyzed for CAT
concentration using a commercial enzyme-linked immunosorbent assay
(Roche Molecular Biochemicals). In all experiments, CAT concentrations
were normalized by total protein content, measured in cell lysates
using the Bradford reagent (Bio-Rad). D10 cells (5 × 107 cells/ml) were separated from irradiated splenocytes by
centrifugation onto a Ficoll-Isopaque gradient (Amersham Pharmacia
Biotech) and then electroporated (960 microfarads, 270 V) with 45 µg
of expression or control plasmids in 0.4 ml of serum-free RPMI using a
Gene Pulser II System (Bio-Rad). Following 20-h recovery in complete medium, D10 cells were seeded on plates coated with 1 µg/ml anti-CD3 antibody (clone 145-2C11; BD PharMingen, San Diego, CA) and then incubated for 16 h prior to RNA extraction.
RNase Protection Analysis--
Total RNA was extracted from D10
cells using RNAzol B (Tel-Test, Inc., Friendswood, TX). Specific
antisense DNA templates for murine IL-4 and for the internal control
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were purchased (BD
PharMingen). These were used to synthesize the
Cellular and Bacterially Expressed Proteins--
Nuclear
extracts were prepared by a modification of a described protocol (26).
Jurkat cells (2-5 × 107) were allowed to swell in 10 mM Hepes, pH 7.9, 30 mM KCl, 1 mM dithiothreitol, 0.2 mM EDTA, 0.5 mM
phenylmethylsulfonyl fluoride, 0.5 µg/ml leupeptin, and 1 µg/ml
aprotinin and then lysed (5 min, 4 °C) by the addition of 0.075%
Nonidet P-40. Nuclei were isolated by centrifugation (4 min, 3,000 rpm)
and then extracted (40 min, 4 °C) in 20 mM Hepes, pH
7.9, 420 mM KCl, 1 mM dithiothreitol, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride,
0.5 µg/ml leupeptin, 1 µg/ml aprotinin, and 20% glycerol. Extracts
were separated from cellular debris and membranes (10 min, 14,000 rpm),
aliquoted, quick-frozen in liquid nitrogen, and then stored at
Electrophoretic Mobility Shift Assay (EMSA)--
The following
oligonucleotides and their complements were synthesized (Genosys
Biotechnologies):
5'-TGCTGAAACTTTGTAGTTAATTTTTTAAAAAGGTTTCATTTTCCTATTGG-3' (225), 5'-AGGTTTCATTTTCCTATTGGTCTGATTTCACAGGAACATTTTACCTGTTT-3' (195), 5'-TCTGATTTCACAGGAACATTTTACCTGTTT-3' (175),
5'-TTGGTCTGATTTCACAGGAACAT-3' (IL-4 CPRE),
5'-TTGGTATTATTTCACAGGAACAT-3' (IL-4 CPRE MUT),
and 5'-TAGAGCAAGCACAAACCAGGCCAA-3' ( Copper-Phenanthroline Footprinting--
Footprinting experiments
were performed as described (27). To identify discrete nucleotide
contacts for rCP2 within the CP2-responsive IL-4 promoter region, a
195-146 oligonucleotide was 5'-end-labeled on the coding or noncoding
strand and then incubated (30 min, 25 °C) with 100 ng of rCP2 in 25 µl of EMSA buffer (described above). Samples were electrophoresed on
a 4% native polyacrylamide gel, which was then immersed into a
solution containing 10 mM Tris, pH 8.0, 0.2 mM
1,10-phenanthroline, and 0.045 mM CuSO4
(Sigma). The chemical nuclease reaction was started by the addition of
mercaptopropionic acid (Sigma) to 0.05%, allowed to proceed for 12 min
at 25 °C, and then quenched in 2 mM
2,9-dimethyl-1,10-phenanthroline (Sigma). Free DNA and DNA-protein
complexes, visualized by autoradiography, were eluted from the gel
matrix (18 h at 37 °C) in 0.5 M ammonium acetate, pH
7.5, 1 mM EDTA, and 0.1% sodium dodecyl sulfate.
Equivalent amounts of DNA from each sample and of a Maxam-Gilbert G+A
ladder of the same probe (27) were resolved by electrophoresis on an 8% acrylamide, 7 M urea gel.
Differential Effect of CP2 Overexpression on the IL-4 and IL-2
Promoters--
Several potential CP2 elements are located within the
proximal 300 bp of the human IL-4 promoter. We analyzed the effect of transient CP2 overexpression on CAT gene expression driven by an IL-4
promoter region included between bp Identification of a CPRE in the IL-4 Promoter--
To map the IL-4
promoter element(s) necessary for transactivation by CP2, we generated
a panel of deletional mutants for use in reporter studies (Fig.
2A) (21). Transiently
overexpressed CP2 was more effective on promoter constructs truncated
at bp
The IL-4 promoter region included between bp
To define the nucleotide contacts necessary for CP2 binding to this
region of the IL-4 promoter, we analyzed the pattern of protection from
chemical cleavage of a 195-146 oligonucleotide following
EMSA with rCP2. In experiments using copper-phenanthroline as the
cleaving agent (27), rCP2 (100 ng) protected a sequence extending from
bp Binding of Endogenous CP2 to the IL-4 CPRE--
A constitutive
CP2-immunoreactive complex was formed in EMSA using a consensus
To elucidate the contribution of endogenously expressed CP2 to
constitutive and inducible activity of the IL-4 promoter, we analyzed
CAT expression in Jurkat cells transiently transfected with plasmids
carrying point mutations within the IL-4 CPRE that would selectively
affect the formation of the CP2-containing complexes. Disruption of the
distal CNRG motif
( IL-4 Transcriptional Repression in T Cells Expressing a CP2
Dominant Negative--
To further assess the contribution of
endogenous CP2 to IL-4 promoter activity, we generated, for use in
transient transfection experiments, a plasmid encoding a CP2
polypeptide lacking the Elf-1 homology region of the DNA-binding domain
(13) and referred to as
Up-regulation of IL-4 promoter activity in CP2-overexpressing Jurkat
cells was often paralleled by markedly increased IL-4 secretion,
suggesting direct activation of the endogenous IL-4 gene (data not
shown). However, due to low level expression of IL-4 and the poor
transfection efficiency in these cells, the effect of overexpressed
In this study, we provide the first evidence of the involvement of
CP2, the prototypical member of a novel family of transcription factors
related to the Drosophila developmental protein Elf-1, in
the regulation of cytokine genes expressed in T cells. CP2 has been
involved in gene regulation in a variety of cell lineages, where it can
act as both a transcriptional activator and a repressor (14, 22, 32,
33). We confirm here the dual nature of this factor, as we found that
CP2 can repress IL-2 promoter activity, while its expression and
function are required for IL-4 promoter-driven transcription in the
human T cell line Jurkat (Figs. 1 and 4A) and for activation
of the endogenous IL-4 gene in the established murine Th2 line D10
(Fig. 4, B and C). These findings point to CP2 as
a specific activator of the IL-4 gene in T cells.
We show that a CPRE is located between bp CP2 represents a novel family of homo-oligomeric transcription factors
binding direct DNA repeats (13, 22). However, heteromeric interaction
of CP2 with Elf-1-related and nonrelated factors, depending on the
promoter context, has also been described (13, 35). In a previous
study, two classes of CPRE have been defined (35). Type I CPRE,
including the high affinity The IL-4 CPRE is surrounded by binding elements for the factors NFAT,
activation protein-1, CBF, interferon response factor-2, and high
mobility group protein I(Y) (30, 31, 36) (Fig. 2C). A CCAAT
box, binding the constitutive factor CBF, lies immediately upstream of
its 5'-end (31). Mutation of a 5-bp cluster spanning bp Our finding of reduced transcriptional activity of constructs carrying
a mutated CPRE demonstrated the critical involvement of endogenous CP2
in IL-4 promoter activity in Jurkat cells. This observation was
confirmed using cells transiently expressing a CP2 mutant having
disrupted DNA binding but intact dimerization domains. The DNA-binding
domain of CP2 includes a region, featuring the highest Elf-1 homology,
that has been reported to be essential for interaction of both CP2 and
Elf-1 with their cognate sites (13, 14). This region, encoded by exon 6 of the CP2 gene and spanning amino acids 189-239, is missing in
several non-DNA-binding CP2 variants, such as LBP-1d, generated in
several cell lines by alternative splicing of CP2 transcripts (11-13).
Some studies have documented the ability of these polypeptides to
function as CP2 antagonists, specifically inhibiting CP2-DNA
interactions in vitro (13, 22). However, the expression
in vivo of sufficiently high levels of these mutants to act
as dominant negatives has not been demonstrated. Here we show that
overexpression of the CP2 is constitutively expressed in the nuclei of Jurkat (Fig.
3A) and D10 cells (not shown), and stimulation did not
affect its expression and/or binding to an
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
, are central
to the development of cell-mediated, delayed type, and autoimmune
responses (2). The biochemical and molecular mechanisms accounting for
polarized expression of cytokine genes in T cells have been the focus
of a number of studies over the past few years (3).
Calcineurin-mediated activation of members of the nuclear factor of
activated T cell (NFAT) family of transcription factors has been
associated with antigen-dependent cytokine gene expression
in both Th1 and Th2 cells (4). However, NFAT-directed IL-4
transcription is preferentially induced in Th2 cells, presumably due to
the involvement of Th2-restricted co-factors (5, 6).
-fibrinogen (15), mouse
-globin (16), simian virus 40 (12), human
immunodeficiency virus-1 (11), herpes simplex virus-1 (17),
- and
-globin, and the human
-like globin gene cluster (18), major
histocompatibility complex class II Ea (19), and human
c-fos and mouse thymidylate synthase (20). However, its contribution to cytokine gene expression in T cells has not been
explored to date. In this study, we investigated the contribution of
CP2 to the mechanisms regulating expression of the two pivotal T
cell-restricted cytokines IL-2 and IL-4.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
following
activation, was a gift by Dr. Jack L. Strominger (Harvard University).
Cells were cultured in RPMI (Mediatech, Herndon, VA), containing 2 mM L-glutamine, 10% heat-inactivated fetal
bovine serum (Gemini Bio-Products, Calabasas, CA), and 50 µg/ml
gentamicin (complete medium). Aliquots of cells frozen at early
passages were recovered from liquid nitrogen and used for experiments
between 1 and 6 weeks after thawing. The murine conalbumin-specific Th2
clone D10.G4.1 (D10; American Type Culture Collection, Manassas, VA)
was maintained in culture by biweekly restimulation with antigen and
irradiated (2,000 rads) syngeneic splenocytes as antigen-presenting
cells in RPMI supplemented with 10% heat-inactivated fetal bovine
serum, 2 mM L-glutamine, 100 units/ml
penicillin, 100 µg/ml streptomycin, and 50 µM
2-mercaptoethanol. IL-4 expression in these cultures was verified using
a sensitive commercial enzyme-linked immunosorbent assay
(Cytoscreen-USTM, BIOSOURCE International,
Camarillo, CA).
741
to
722,
311 to
292,
265 to
246,
225 to
206,
175 to
156,
145 to
126,
95 to
76, or
65 to
46, were used to
introduce the appropriate restriction sites at the invariant 3'- and at the 5'-ends, respectively. After sequence verification, each fragment was inserted into the HindIII and XbaI sites of
the chloramphenicol acetyltransferase (CAT)-expressing reporter vector,
pCAT-Basic (Promega, Madison, WI) to construct the corresponding
reporter plasmids IL-4.741, IL-4.311,
IL-4.265, IL-4.225, IL-4.175,
IL-4.145, IL-4.95, and IL-4.65 (21).
An IL-4.225 plasmid carrying two point mutations within the
CP2-response element (CPRE) was generated by site-directed mutagenesis
(QuikChangeTM; Stratagene). The following mutagenic primer (mutations
are underlined) and its complement were synthesized (Genosys
Biotechnologies, The Woodlands, TX): 5'-CATTTTCCTATTGGTATTATTTCACAGGAACATTTTACCTG-3'.
The CP2 expression plasmid was generated by insertion of the murine CP2
cDNA into the HindIII and NotI sites of a
pRc/CMV vector (Invitrogen, San Diego, CA) (14). A CP2 mutant lacking
the Elf-1-homologous region of the DNA-binding domain
(
Elf-1) was generated from a full-length template as
described (22) and inserted into the same vector. The
IL-2.15
CX reporter plasmid, bearing bp
319 to
+52 of the human IL-2 gene in pCAT-Basic (23), has been kindly donated by Dr. Gerald R. Crabtree (Stanford University, Stanford, CA).
-[32P]UTP (3,000 Ci/mmol, 10 mCi/ml; Amersham
Pharmacia Biotech)-labeled probes in the presence of a GACU pool using
a T7 RNA polymerase (Promega). Riboprobes (500,000 cpm) were hybridized
with 5-15 µg of target RNA at 45 °C, followed by digestion with
RNase A (Promega) for 30 min at 30 °C as described (25). The samples were loaded on an acrylamide-urea sequencing gel next to labeled DNA
molecular weight markers and next to the labeled probes and run
at 50 watts in 45 mM Tris, pH 8.2, 45 mM boric
acid, and 1 mM EDTA. The gel was adsorbed to filter paper,
dried under vacuum, and exposed to film (X-OmatTM AR;
Eastman Kodak Co.) at
70 °C with an intensifying screen. Autoradiographs were quantified by computerized densitometry using a
Kodak Digital Science Electrophoresis Documentation and Analysis System. Results are shown as the ratio of IL-4/GAPDH densitometric units.
80 °C. Protein concentrations in all extracts were measured by the
Bradford protocol (Bio-Rad). Recombinant CP2 (rCP2) was prepared and
enriched as described previously (14).
-globin CPRE). These were
either 5'-end-labeled using T4 polynucleotide kinase (New England
Biolabs, Beverly, MA) and [
-32P]ATP or labeled by
random hexamer priming using the Klenow fragment (Roche Molecular
Biochemicals) and [
-32P]dCTP (Amersham Pharmacia
Biotech). In both cases, radiolabeled probes were purified by spin
column chromatography (ProbeQuant; Amersham Pharmacia Biotech) and then
by electroelution from 4% nondenaturing polyacrylamide gels. For EMSA,
probes (10,000-30,000 cpm, corresponding to 5-20 fmol) were incubated
(20-30 min, 25 °C) with 1-5 µg of nuclear extracts or 10-100 ng
of rCP2 in 15 µl of 12 mM Hepes, pH 7.9, 50 mM KCl, 0.5 mM MgCl2, 0.12 mM EDTA, 0.12 mM EGTA, 4 mM
dithiothreitol, 0.1% Nonidet P-40, 12% glycerol, 0.1 mg/ml bovine
serum albumin, and 30 µg/ml (10 µg/ml in the case of rCP2)
poly(dI-dC) (Amersham Pharmacia Biotech). Where indicated, 20 min after
the addition of the probe, the binding reactions were incubated (30 min, 4 °C) with rabbit antisera specific for the transcription
factors CP2 (16), NFAT-1 (Upstate Biotechnology, Inc., Lake Placid,
NY), CCAAT-binding factor (CBF)-A (Accurate Chemical & Scientific,
Westbury, NY), or signal transducer and activator of transcription 6 (STAT6) (Santa Cruz Biotechnologies, Inc., Santa Cruz, CA). This led,
under the experimental conditions described, to ablation of the
immunoreactive complexes, with almost no detectable "supershift"
(14). Free probes and DNA-protein complexes were resolved by
electrophoresis on 4% native polyacrylamide gels in 45 mM
Tris, pH 8.2, 45 mM boric acid, 1 mM EDTA, and
1% glycerol and then visualized by autoradiography of fixed and dried gels.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
311 and +55 in the human T cell
line Jurkat. In agreement with previous studies (24, 28, 29), we found
that these cells are in a preactivated state with respect to IL-4
expression, characterized by constitutively elevated IL-4 mRNA
accumulation (data not shown) and promoter activity (Fig.
1). Constitutive IL-4 promoter activity
was enhanced up to 5-fold in Jurkat cells transiently transfected with
a CP2 expression plasmid (Fig. 1). CP2 overexpression resulted in less noticeable increase of IL-4 promoter activity in cells stimulated with
PMA (10 ng/ml) and the Ca2+ ionophore A23187 (1 µM), presumably due to the contribution of endogenous CP2
to IL-4 activation in these cells (see below). In striking contrast,
PMA- and A23187-induced IL-2 promoter activity was reduced by up to
80% in CP2-overexpressing cells (Fig. 1).

View larger version (17K):
[in a new window]
Fig. 1.
The effect of CP2 overexpression on IL-4 and
IL-2 promoter activity. The CAT reporter plasmids
IL-4.311 (IL-4), bearing bp -311 to +55 of the
human IL-4 gene, or IL-2.15
CX (IL-2),
including bp
319 to +52 of the human IL-2 gene, were transiently
transfected (1 µg each) in Jurkat cells (106/ml) along
with 2 µg of a CP2 expression plasmid or the corresponding noncoding
vector (pRc/CMV). Cells were left uninduced (open bars) or
stimulated for 18 h with 10 ng/ml PMA and 1 µM
A23187 (closed bars). Shown is mean ± S.E. CAT
concentration in cell lysates, normalized by total protein, in three
independent experiments.
265 or
225 than on IL-4.311 or IL-4.741
(Fig. 2B). However, removal of the region spanning bp
225
to
176 decreased transcriptional activation in CP2-overexpressing
cells by almost 4-fold, while constructs truncated at bp
145 through
65 were unresponsive to the factor (Fig. 2B). This
indicated that a CPRE is located between bp
175 and
146, although
additional nucleotide contacts upstream of bp
175 might be required
for full promoter inducibility by CP2.

View larger version (52K):
[in a new window]
Fig. 2.
Identification of a CPRE in the human IL-4
promoter. A, schematic representation of the human IL-4
promoter and of the polymerase chain reaction-generated fragments
bearing 5' deletions to the indicated bp upstream of the IL-4 gene
transcription initiation site. Insertion into pCAT-Basic generated the
reporter constructs IL-4.741 (not shown),
IL-4.311, IL-4.265, IL-4.225,
IL-4.175, IL-4.145, IL-4.95, and
IL-4.65. Open and closed
rectangles indicate the relative positions of positive and
negative regulatory elements, respectively, identified to date in the
IL-4 promoter. P0-P4, the five NFAT-binding P sequences
(30); CCAAT, binding elements for CBF (31).
Octamer-associated protein (OAP) and c-Maf response element
(MARE) bind activation protein-1 family members
(i.e. JunB) and the related proto-oncoprotein c-Maf,
respectively (5, 6). The negative regulatory elements (NRE-I
and -II) bind as yet unidentified transcriptional
repressor(s) (29). Interferon stimulation-response element
(ISRE) is a negative regulatory interferon-responsive
factor-2-binding element (31). Box II, A/T-rich region
contributing to repression by high mobility group protein I(Y) (36).
B, Jurkat cells were transiently transfected with 1 µg
each of the indicated human IL-4 promoter constructs and 2 µg of a
pRc/CMV-CP2 expression vector or its corresponding noncoding control
(dashed line). Shown is mean ± S.E. -fold induction of
control CAT expression in three independent experiments. C,
sequence of the region required for IL-4 promoter activation by
overexpressed CP2. The relevant elements and their cognate
transcription factors are indicated. Shown is, among other elements
also indicated in a, the recently identified P2 negative
regulatory element (NRE), binding the putative
transcriptional repressor Rep-1 (21). Also shown is a schematic
representation of three oligonucleotides (225-176,
195-146, and 175-146), spanning promoter
subregions included between the indicated bp, that were used as probes
in EMSA using rCP2. HMG I(Y), high mobility group protein
I(Y); IRF-2, interferon-responsive factor-2;
ISRE, interferon stimulation-response element. D,
shown for comparison (lane 1) is the binding of
rCP2 (100 ng) to an oligonucleotide probe including the proximal
-globin CP2 consensus site. The formation of a complex with CP2
homodimers is indicated. E, copper-phenanthroline
footprinting of a 195-146 oligonucleotide, 5'-end-labeled on the coding strand. Following EMSA with rCP2,
free (F) and bound DNA (CP2) were cleaved within
the gel matrix and then eluted and electrophoresed on an 8% sequencing
gel. The alignment with a Maxam-Gilbert ladder (G+A) of the
same probe is shown. Positions relative to the IL-4 transcription
initiation site are indicated to the left. A hypersensitive
site at bp
151 and a footprint extending from bp
177 to
158 are
indicated to the right as an asterisk and a
dashed line, respectively. F, the
CP2-protected sequence is aligned with a series of CPREs identified in
several cellular and viral promoters. The CNRG repeats (see
"Discussion") are indicated in boldface
letters. Shown are the distal and proximal CPRE from the
mouse
-globin promoter, the high affinity sites from the rat
-fibrinogen promoter and the human immunodeficiency virus-1
long-terminal repeat, and a low affinity site from the major
histocompatibility complex class II Ea proximal promoter. Also shown is
an element within the mouse steroid 16
-hydroxylase gene
(Cyp 2d-9) that interacts with the CP2-related protein
LBP-1a (41).
225 and
146, shown in
Fig. 2C, harbors a number of elements contributing to a
varying degree to IL-4 transcriptional activation (21, 30, 31). To
verify whether CP2 can directly bind to elements located within this
IL-4 promoter region, we generated three oligonucleotides spanning
partially overlapping sequences for use in EMSA (Fig. 2C).
rCP2, used at a concentration (100 ng/15 µl) sufficient for saturation of an
-globin consensus oligonucleotide (Fig.
2D, lane 1), did not bind to
oligonucleotides 175-146 (lane 2) and 225-176 (lane 4). Since nucleotide
contacts in both subregions might be required for CP2 binding, we also
used as a probe an oligonucleotide (195-146) including the
proximal 20 bp of the 225-176 segment in addition to
175-146 (Fig. 2C). This resulted in consistent formation of
a CP2 complex of apparently lower affinity than that formed on the
-globin probe (Fig. 2D, lane 3). A
complex of faster mobility also formed on the
195-146 oligonucleotide, which was accounted for
by binding of monomeric CP2, as assessed by coincubation with
CP2-specific antibodies (data not shown).
177 to
158 (Fig. 2E). A CPRE
(
174CTGATTTCACAGG
162) is recognizable
within this sequence. Its homology to CP2 elements identified within
other cellular and viral promoters is shown in Fig. 2F. The
IL-4 CPRE displays a conserved (
165CAGG
162)
and an imperfect CNRG motif (
174CTGA
171)
separated by a 5-bp linker.
-globin CP2 oligonucleotide and nuclear extracts from Jurkat cells
(Fig. 3, A and B).
CP2 nuclear expression and/or DNA binding activity in these cells was
not affected by stimulation with PMA and A23187 (Fig. 3A,
lanes 2 and 3). Four complexes were
detectable in EMSA with Jurkat nuclear extracts and a similar length
oligonucleotide probe centered on the IL-4 promoter CPRE (lanes 4-6). Differently from the
-globin
complex, Ca2+-mediated stimulation did affect formation of
the slower mobility complexes I and II, with consistently increased
formation of complex II and diminished complex I formation
(lane 5). Both complexes appeared to contain
immunoreactive CP2, as indicated by the neutralizing effect of rabbit
anti-CP2 antibodies (Fig. 3B, lane 6),
while neither complex reacted to CBF-A-, NFAT-1-, or STAT6-specific antibodies (lanes 7 and 8 and data not
shown). Complexes III and IV apparently consisted of unrelated
constitutive nuclear protein(s) of unclear sequence specificity.

View larger version (44K):
[in a new window]
Fig. 3.
Binding of endogenous CP2 to the IL-4 CPRE
and its contribution to promoter activity. A, EMSA
using nuclear proteins (5 µg/lane) extracted from Jurkat cells
treated as indicated and oligonucleotide probes spanning the proximal
-globin (lanes 1-3) or the IL-4 CPRE
(lanes 4-6). The
-globin CP2 complex is
indicated to the left. Four complexes (I-IV)
forming on the IL-4 CPRE are indicated to the right.
B, following incubation with the DNA probes, nuclear
extracts from unstimulated Jurkat cells were incubated with rabbit
preimmune IgG (R-IgG; lanes 1 and
5) or the indicated factor-specific antibodies (1 µg/lane). Immunoreactive CP2 is detected within the
-globin CP2
complex and in the IL-4 complexes I and II (lanes
2 and 6). C, nuclear extracts (5 µg/lane) from unstimulated Jurkat cells were incubated with a
wild-type (WT) IL-4 CPRE oligonucleotide or with a similar
oligonucleotide (MUT) carrying two point mutations within
the CPRE (see "Results"). The same mutation was introduced
within an IL-4.225 construct by site-directed mutagenesis.
D, CAT expression in Jurkat cells transiently transfected
with the wild-type (WT) or mutant (MUT)
IL-4.225 and left uninduced (open bars) or
treated with 1 µM A23187 (closed
bars). Mean ± S.E. of three independent experiments is
shown.
174ATTATTTCACAGG
162)
was sufficient to markedly decrease CP2 binding in EMSA using Jurkat
nuclear extracts (Fig. 3C) or rCP2 (not shown). This was accompanied by an almost 50% decrease in constitutive and induced CAT
expression in Jurkat cells transiently transfected with an IL-4.225 plasmid carrying the same mutation within the CPRE
(Fig. 3D).
Elf-1 mutant. In a previous
study, this mutant did not bind to DNA and specifically inhibited
binding of full-length CP2 in a dominant negative fashion (22). Its
overexpression inhibited by >75% constitutive IL-4 promoter activity
in Jurkat cells (Fig. 4A). A
similar degree of IL-4 promoter inhibition was seen in cells stimulated
with A23187, while IL-2 promoter activity was fundamentally unaffected
(data not shown).

View larger version (12K):
[in a new window]
Fig. 4.
Dominant negative effect of the CP2
Elf-1 mutant. A,
full-length CP2 (CP2) or the
Elf-1 CP2 variant
(see "Results") was cloned into pRc/CMV and transiently
transfected in Jurkat cells together with an IL-4.311
construct. Mean ± S.E. -fold induction of CAT expression relative
to noncoding controls (dashed horizontal line) in three
independent experiments is shown. B, a full-length
(CP2) or
Elf-1 expression plasmid or the
corresponding noncoding vector (Control) was transfected (45 µg each) in D10 cells as indicated. IL-4 and GAPDH transcripts were
detected by RNase protection of total RNA extracted from these cells
16 h after stimulation with 1 µg/ml plate-bound anti-CD3
antibodies (see "Experimental Procedures"). Shown is a typical
experiment out of three performed. C, the relative amounts
of IL-4 and GAPDH RNA in these experiments were measured by
densitometry (see "Experimental Procedures"). The ratios of IL-4 to
GAPDH RNA densitometric units were calculated for each sample and
expressed as -fold induction over samples transfected with control
vector (dashed horizontal line). Bars represent
the mean ± S.E. of three independent experiments.
Elf-1 CP2 was far less apparent (not shown). To elucidate
the role of CP2 in transcriptional activation of the endogenous IL-4
gene, we therefore assessed the effect of overexpressed CP2
polypeptides on IL-4 transcript accumulation in the murine Th2 cell
line D10. As shown in Fig. 4, B and C, D10 cells
transfected to higher than 50% efficiency with a full-length CP2-encoding plasmid expressed, upon CD3 ligation, markedly higher levels of IL-4 mRNA than cells transfected with the corresponding noncoding plasmid. In contrast, and in clear agreement with our findings shown in Fig. 4A, overexpression of the dominant
negative
Elf-1 mutant consistently interfered with
CD3-dependent activation of the IL-4 gene in D10 cells.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
177 and
158 of the human
IL-4 promoter, a region previously shown to be required for maximal
promoter activation in Th cells (30, 34). The IL-4 CPRE
(
174CTGATTTCACAGG
162) only diverges by 1 bp
from the reported CP2 consensus (Fig. 2F), which was defined
by assessing the effect of in-frame clustered mutations within high
affinity CP2 sites, such as the proximal
-globin site or the
-fibrinogen site, on rCP2 binding in EMSA (14). While the nucleotide
composition of the linker sequence was found to only marginally affect
CP2 binding, spacing of the two CNRG motifs was critical for the
stability of the CP2-DNA complex (14). Thus, CNRG repeats separated by
5 bp, such as the
-globin distal CPRE (Fig. 2F), can bind
CP2 with about 4-fold lower affinity than elements containing a linker
of 6 bp (14). Consistent with this view, the IL-4 CPRE, featuring a
5-bp linker, bound rCP2 with apparently lower affinity than the
proximal
-globin site (Fig. 2D).
-globin and
-fibrinogen sites,
preferentially bind CP2 as a homodimer or homotetramer (20), while type
II CPRE, including sites within the
- and
-globin promoters, bind
CP2 as an obligate heterodimer (35). Our findings show that the IL-4
CPRE behaves as a type II site. In fact, while rCP2 homodimers bind to
this site with relatively low affinity, native CP2 accounts for the
formation of two complexes having noticeably slower mobility than the
complex formed on an
-globin type I site (Fig. 3, A and
B) or in EMSA using rCP2 (Fig. 2D). This suggests
that additional factor(s) might contribute to CP2 interaction with an
otherwise low affinity site. Consistent with this view,
Ca2+-mediated stimulation of Jurkat cells, while not
affecting CP2 binding to the
-globin site, led to increased
formation of a major IL-4 complex, with decreased formation of an
additional, slower mobility complex (Fig. 3A). This suggests
the involvement of a Ca2+-regulated, as yet unknown
heteromeric co-factor(s) in CP2 interaction with the IL-4 promoter.
178 to
174,
thereby disrupting this CCAAT box and the distal CNRG motif of the
CPRE, resulted in 40% reduction of overall IL-4 promoter activity in
Jurkat cells (31). We show (Fig. 3D) that the isolated
disruption of the IL-4 CPRE is sufficient to produce a similar or
greater decrease of promoter activity (~50%) in the same cellular
host. Although CP2 and CBF, also known as CP1 or nuclear factor-Y, also
bind to adjacent elements in the
-globin promoter (37), the two
factors form mutually exclusive complexes on oligonucleotides including
these elements (22). The 3'-half of the CPRE partially overlaps the
NFAT-binding P2 sequence and a consensus STAT6 element (38). However,
CP2 does not apparently interact with NFAT or STAT6 in EMSA using
oligonucleotides including both the CPRE and the P2 sequence (data not shown).
Elf-1 mutant markedly represses
IL-4 promoter activity in Jurkat cells as well as IL-4 gene expression
in activated D10 cells (Fig. 4), stressing the role of CP2 in the
activation of the IL-4 gene in T cells. Use of this dominant negative
in vivo should provide a valuable tool to understand the
role of CP2 in differential cytokine gene expression in Th cell clones.
-globin consensus in
EMSA. Our data suggest that inducible co-factor(s) stabilize CP2
binding to the IL-4 CPRE and contribute to IL-4 activation in
stimulated cells. Jurkat cells are in a preactivated state with respect
to IL-4 transcription and the nuclear expression of NFAT or other IL-4
promoter-binding factors (29, 39). Interestingly, both IL-4 expression
and CP2 binding activity are induced by mitogenic stimulation of
circulating naive Th cells in a cell cycle-dependent fashion (8, 10). Consistent with these findings, histone deacetylase
inhibitors, such as butyrate, can supplant the cell cycle requirements
for both IL-4 transcription and CP2 activation (8, 40). In conclusion,
our findings support the hypothesis that CP2 expression and DNA-binding
activity in T cells are correlated with IL-4 gene expression and point
to CP2 as an important participant in the mechanisms regulating Th cell
differentiation in the periphery.
| |
ACKNOWLEDGEMENTS |
|---|
We are grateful to Dr. Lawrence M. Lichtenstein for support throughout the study. We thank Drs. Gerald R. Crabtree and Jack L. Strominger for the generous gift of reagents; Jaimee S. Reynolds and John W. Schmidt for excellent technical assistance; and Sarki A. Abdulkadir, Antonella Cianferoni, David M. Essayan, Shau-Ku Huang, David G. Marsh, Anjana Rao, Robert P. Schleimer, John T. Schroeder, Dinah S. Singer, Cristiana Stellato, and Dimitris Thanos for helpful discussions and comments.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grants AI41463 (to V. C.), AI01152 (to S. N. G.), GM49661, EY1901, EY12523, and CA89559 (to S. J. O.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed. Tel.: 410-550-2068; Fax: 410-550-2090; E-mail: casolaro@mail.jhmi.edu.
** Supported by a fund from the Lucille P. Markey Charitable Trust (Miami, FL).
Published, JBC Papers in Press, September 5, 2000, DOI 10.1074/jbc.M007086200
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
IL, interleukin;
bp, base pair(s);
CAT, chloramphenicol acetyltransferase;
CBF, CCAAT-binding factor;
CPRE, CP2-response element;
Elf-1, CP2 mutant lacking the Elf-1-homologous region of the DNA-binding
domain;
EMSA, electrophoretic mobility shift assay;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
LBP, leader-binding protein;
NFAT, nuclear factor of activated T cells;
rCP2, recombinant CP2;
STAT, signal transducer and activator of transcription;
Th, T helper;
CMV, cytomegalovirus.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Boulay, J.-L., and Paul, W. E. (1992) J. Biol. Chem. 264, 20525-20528 |
| 2. | O'Garra, A. (1998) Immunity 8, 275-283 |
| 3. | Fitch, F. W., McKisic, M. D., Lancki, D. W., and Gajewski, T. F. (1993) Annu. Rev. Immunol. 11, 29-48 |
| 4. | Rao, A., Luo, C., and Hogan, P. G. (1997) Annu. Rev. Immunol. 15, 707-747 |
| 5. | Li, B., Tournier, C., Davis, R. J., and Flavell, R. A. (1999) EMBO J. 18, 420-432 |
| 6. | Ho, I.-C., Hodge, M. R., Rooney, J. W., and Glimcher, L. H. (1996) Cell 85, 973-983 |
| 7. | Weinberg, A. D., English, M., and Swain, S. L. (1990) J. Immunol. 144, 1800-1807 |
| 8. | Bird, J. J., Brown, D. R., Mullen, A. C., Moskowitz, N. H., Mahowald, M. A., Sider, J. R., Gajewski, T. F., Wang, C. R., and Reiner, S. L. (1998) Immunity 9, 229-237 |
| 9. | Cron, R. Q., Bort, S. J., Wang, Y., Brunvand, M. W., and Lewis, D. B. (1999) J. Immunol. 162, 860-870 |
| 10. | Volker, J. L., Rameh, L. E., Zhu, Q., DeCaprio, J., and Hansen, U. (1997) Genes Dev. 11, 1435-1446 |
| 11. | Yoon, J.-B., Li, G., and Roeder, R. G. (1994) Mol. Cell. Biol. 14, 1776-1785 |
| 12. | Shirra, M. K., Zhu, Q., Huang, H.-C., Pallas, D., and Hansen, U. (1994) Mol. Cell. Biol. 14, 5076-5087 |
| 13. | Uv, A. E., Thompson, C. R. L., and Bray, S. J. (1994) Mol. Cell. Biol. 14, 4020-4031 |
| 14. | Lim, L. C., Fang, L., Swendeman, S. L., and Sheffery, M. (1993) J. Biol. Chem. 268, 18008-18017 |
| 15. | Chodosh, L. A., Baldwin, A. S., Carthew, R. W., and Sharp, P. A. (1988) Cell 53, 11-24 |
| 16. | Lim, L. C., Swendeman, S. L., and Sheffery, M. (1992) Mol. Cell. Biol. 12, 828-835 |
| 17. | Dabrowski, C. E., Carmillo, P. J., and Schaffer, P. A. (1994) Mol. Cell. Biol. 14, 2545-2555 |
| 18. | Cunningham, J. M., and Jane, S. M. (1995) Blood 86 Suppl. 1, 4 (abstr.) |
| 19. | Bellorini, M., Dantonel, J. C., Yoon, J.-B., Roeder, R. G., Tora, L., and Mantovani, R. (1996) Mol. Cell. Biol. 16, 503-512 |
| 20. | Shirra, M. K., and Hansen, U. (1998) J. Biol. Chem. 273, 19260-19268 |
| 21. | Georas, S., Cumberland, J., Burke, T., Park, E., Ono, S., and Casolaro, V. (2000) Leukemia 14, 629-635 |
| 22. | Zhong, F., Swendeman, S. L., Popik, W., Pitha, P. M., and Sheffery, M. (1994) J. Biol. Chem. 269, 21269-21276 |
| 23. | Shaw, J.-P., Utz, P. J., Durand, D. B., Toole, J. J., Emmel, E. A., and Crabtree, G. R. (1988) Science 241, 202-205 |
| 24. | Casolaro, V., Georas, S. N., Song, Z., Zubkoff, I. D., Abdulkadir, S. A., Thanos, D., and Ono, S. J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11623-11627 |
| 25. | Song, Z., Krishna, S., Thanos, D., Strominger, J. L., and Ono, S. J. (1994) J. Exp. Med. 180, 1763-1774 |
| 26. | Li, Y., Ross, J., Scheppler, J. A., and Franza, B. R., Jr. (1991) Mol. Cell. Biol. 11, 1883-1893 |
| 27. | Sigman, D. S. (1990) Biochemistry 29, 9097-9105 |
| 28. | Arai, N., Nomura, D., Villaret, D., DeWaal-Malefijt, R., Seiki, M., Yoshida, M., Minoshima, S., Fukuyama, R., Maekawa, M., Kudoh, J., Shimizu, N., Yokota, K., Abe, E., Yokota, T., Takebe, Y., and Arai, K. (1989) J. Immunol. 142, 274-282 |
| 29. | Li-Weber, M., Eder, A., Krafft-Czepa, H., and Krammer, P. H. (1992) J. Immunol. 148, 1913-1918 |
| 30. | Takemoto, N., Koyano-Nakagawa, N., Arai, N., Arai, K., and Yokota, T. (1997) Int. Immunol. 9, 1329-1338 |
| 31. | Li-Weber, M., Davydov, I. V., Krafft, H., and Krammer, P. H. (1994) J. Immunol. 153, 4122-4133 |
| 32. | Parada, C. A., Yoon, J. B., and Roeder, R. G. (1995) J. Biol. Chem. 270, 2274-2283 |
| 33. | Cunningham, J. M., Vanin, E. F., Tran, N., Valentine, M., and Jane, S. M. (1995) Genomics 30, 398-399 |
| 34. | Lederer, J. A., Perez, V. L., DesRoches, L., Kim, S. M., Abbas, A. K., and Lichtman, A. H. (1996) J. Exp. Med. 184, 397-406 |
| 35. | Jane, S. M., Nienhuis, A. W., and Cunningham, J. M. (1995) EMBO J. 14, 97-105 |
| 36. | Klein-Hessling, S., Schneider, G., Heinfling, A., Chuvpilo, S., and Serfling, E. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 15311-15316 |
| 37. | Kim, C. G., Swendeman, S. L., Barnhart, K. M., and Sheffery, M. (1990) Mol. Cell. Biol. 10, 5958-5966 |
| 38. | Georas, S. N., Cumberland, J. E., Burke, T. F., Chen, R., Schindler, U., and Casolaro, V. (1998) Blood 92, 4529-4538 |
| 39. | Lederer, J. A., Liou, J. S., Todd, M. D., Glimcher, L. H., and Lichtman, A. H. (1994) J. Immunol. 152, 77-86 |
| 40. | Ikuta, T., Atweh, G., Boosalis, V., White, G. L., Da Fonseca, S., Boosalis, M., Faller, D. V., and Perrine, S. P. (1998) Ann. N. Y. Acad. Sci. 850, 87-99 |
| 41. | Sueyoshi, T., Kobayashi, R., Nishio, K., Aida, K., Moore, R., Wada, T., Handa, H., and Negishi, M. (1995) Mol. Cell. Biol. 15, 4158-4166 |
This article has been cited by other articles:
![]() |
A. H.-M. Tan, S.-C. Wong, and K.-P. Lam Regulation of Mouse Inducible Costimulator (ICOS) Expression by Fyn-NFATc2 and ERK Signaling in T Cells J. Biol. Chem., September 29, 2006; 281(39): 28666 - 28678. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. N. Georas, J. Guo, U. De Fanis, and V. Casolaro T-helper cell type-2 regulation in allergic disease Eur. Respir. J., December 1, 2005; 26(6): 1119 - 1137. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Sato, K.-i. Yasumoto, K. Kimura, K. Numayama-Tsuruta, and K. Sogawa Heterodimerization with LBP-1b is necessary for nuclear localization of LBP-1a and LBP-1c Genes Cells, September 1, 2005; 10(9): 861 - 870. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. C. Kang, J. H. Chae, Y. H. Lee, M.-A. Park, J. H. Shin, S.-H. Kim, S.-K. Ye, Y. S. Cho, S. Fiering, and C. G. Kim Erythroid Cell-Specific {alpha}-Globin Gene Regulation by the CP2 Transcription Factor Family Mol. Cell. Biol., July 15, 2005; 25(14): 6005 - 6020. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ylisastigui, R. Kaur, H. Johnson, J. Volker, G. He, U. Hansen, and D. Margolis Mitogen-Activated Protein Kinases Regulate LSF Occupancy at the Human Immunodeficiency Virus Type 1 Promoter J. Virol., May 15, 2005; 79(10): 5952 - 5962. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Acloque, A. Mey, A. M. Birot, H. Gruffat, B. Pain, and J. Samarut Transcription factor cCP2 controls gene expression in chicken embryonic stem cells Nucleic Acids Res., April 23, 2004; 32(7): 2259 - 2271. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Venkatesan, H. R. McManus, C. C. Mello, T. F. Smith, and U. Hansen Functional conservation between members of an ancient duplicated transcription factor family, LSF/Grainyhead Nucleic Acids Res., August 1, 2003; 31(15): 4304 - 4316. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Frith, J. L. Spouge, U. Hansen, and Z. Weng Statistical significance of clusters of motifs represented by position specific scoring matrices in nucleotide sequences Nucleic Acids Res., July 15, 2002; 30(14): 3214 - 3224. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tuckfield, D. R. Clouston, T. M. Wilanowski, L.-L. Zhao, J. M. Cunningham, and S. M. Jane Binding of the RING Polycomb Proteins to Specific Target Genes in Complex with the grainyhead-Like Family of Developmental Transcription Factors Mol. Cell. Biol., March 15, 2002; 22(6): 1936 - 1946. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. E. Drouin, C. E. Schrader, J. Stavnezer, and U. Hansen The Ubiquitously Expressed DNA-Binding Protein Late SV40 Factor Binds Ig Switch Regions and Represses Class Switching to IgA J. Immunol., March 15, 2002; 168(6): 2847 - 2856. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Guo, V. Casolaro, E. Seto, W.-M. Yang, C. Chang, M.-C. Seminario, J. Keen, and S. N. Georas Yin-Yang 1 Activates Interleukin-4 Gene Expression in T Cells J. Biol. Chem., December 21, 2001; 276(52): 48871 - 48878. [Abstract] [Full Text] [PDF] |
||||
| |||||